Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

manilatimes.net · 2026-10-27

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited ('Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer ('NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on Thursday, November 5, 2026, at 4:30 pm HKT /8:30 am GMT / 3:30 am EST.

TickrTrends take: HUTCHMED's presentation of savolitinib clinical data in non-small cell lung cancer represents a potential value driver for AZN, which acquired HUTCHMED in 2021. Given TickrTrends' undervalued assessment of AZN, investors monitoring the Healthcare sector should track whether positive clinical data from this event could support pipeline strength and justify current valuations. The expert insights event provides an opportunity for the market to reassess the commercial potential of this asset within AZN's oncology portfolio.

Read the full story at manilatimes.net →